Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives.

Ther Clin Risk Manag · 2019 · PMC6666377 · PMID 31440057

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

8 This was highly significant, and led to the registration of everolimus for the treatment of intractable epilepsy in patients with TSC aged 2 years and older.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.